NSCLC新辅助免疫治疗有专家共识了!9条共识的要点梳理
转自 医粒种子刚刚牛!奥希替尼攻克EGFR最难治突变20ins,张力教授团队中国数据结果出炉,疾病控制率100%!
转自 三毛99刚刚盘点:PD-1/PD-L1遭遇失败的13项III期临床研究
转自 rodneyzhang刚刚大汇总:非小细胞肺癌EGFR18-20外显子突变与TKI疗效
转自 生物_医药_科研刚刚Afatinib用于晚期肺鳞癌二线治疗:革命是否成功 --LUX-lung 8研究深度解读
转自 海上游魂刚刚KEYNOTE158
转自 tianjinjs7y90o刚刚波齐替尼Poziotinib详解
转自 glc198512刚刚肺印戒细胞癌
阅144转1刚刚Dabrafenib plus trametinib in patients with previously untreated BRAFV600E
阅123转1刚刚国际文传: Real
阅29转0刚刚2018 ASCO揭秘奥希替尼的耐药机制
阅401转3刚刚2018上半年好电影收藏
阅13转0刚刚Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
阅130转2刚刚Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non
阅42转1刚刚Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
阅19转1刚刚Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive
阅61转1刚刚AAGL:子宫内膜息肉临床实践指南(2015版)
转自 付霞霏刚刚含有实性和微乳头成分的非小细胞肺癌预后差
阅55转0刚刚Lean body mass
阅139转0刚刚Combined VEGF and PD-1
阅72转0刚刚
-
设计心理学2:与复杂共处